1. ML B, SLN M, ER A, TR M, AM K, XO B. Multidimensional communication in the microenvirons of glioblastoma. Nature reviews Neurology. 2018;14(8):482-495.
2. Georgescu M, Olar A. Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma. Acta neuropathologica communications. 2020;8(1):10. doi:10.1186/s40478-020-0889-x
3. BM A, TF C. Adult Glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(21):2402-2409.
4. Park J, Kim H, Kim N, Park S, Kim Y, Kim J. Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Is Associated with Patient Outcomes in IDH-Wildtype Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021;27(1):237-245. doi:10.1158/1078-0432.Ccr-20-2156
5. Lasocki A, Gaillard F. Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research. AJNR American journal of neuroradiology. 2019;40(5):758-765. doi:10.3174/ajnr.A6025
6. Jiang H, Cui Y, Liu X, Ren X, Li M, Lin S. Proliferation-dominant high-grade astrocytoma: survival benefit associated with extensive resection of FLAIR abnormality region. J Neurosurg. Mar 22 2019:1-8. doi:10.3171/2018.12.Jns182775
7. Choi Y, Ahn K, Nam Y, et al. Analysis of heterogeneity of peritumoral T2 hyperintensity in patients with pretreatment glioblastoma: Prognostic value of MRI-based radiomics. European journal of radiology. 2019;120:108642. doi:10.1016/j.ejrad.2019.108642
8. Lasocki A, Gaillard F, Tacey M, Drummond K, Stuckey S. Multifocal and multicentric glioblastoma: Improved characterisation with FLAIR imaging and prognostic implications. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2016;31:92-8. doi:10.1016/j.jocn.2016.02.022
9. Barajas R, Hodgson J, Chang J, et al. Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology. 2010;254(2):564-76. doi:10.1148/radiol.09090663
10. Lasocki A, Gaillard F, Tacey M, Drummond K, Stuckey S. The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma. Journal of neuro-oncology. 2016;129(3):471-478. doi:10.1007/s11060-016-2193-y
11. Jiang H, Yu K, Li M, et al. Classification of Progression Patterns in Glioblastoma: Analysis of Predictive Factors and Clinical Implications. Front Oncol. 2020;10:590648. doi:10.3389/fonc.2020.590648
12. Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. Jul 20 2017;35(21):2439-2449. doi:10.1200/jco.2017.72.7511
13. Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics. Apr 2017;14(2):307-320. doi:10.1007/s13311-016-0507-6
14. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. Apr 10 2010;28(11):1963-72. doi:10.1200/jco.2009.26.3541
15. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. Jun 29 2021;doi:10.1093/neuonc/noab106
16. Li M, Dong G, Zhang W, et al. Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma. Cancer Sci. Jun 11 2021;doi:10.1111/cas.15024
17. Li M, Ren X, Jiang H, et al. Supratentorial high-grade astrocytoma with leptomeningeal spread to the fourth ventricle: a lethal dissemination with dismal prognosis. J Neurooncol. Apr 2019;142(2):253-261. doi:10.1007/s11060-018-03086-8
18. Li M, Ren X, Dong G, et al. Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features. Front Oncol. 2021;11:627325. doi:10.3389/fonc.2021.627325
19. van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology. Jun 2011;12(6):583-93. doi:10.1016/s1470-2045(11)70057-2
20. Yang K, Ren X, Tao L, et al. Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. Feb 2019;31(1):188-202. doi:10.21147/j.issn.1000-9604.2019.01.14
21. Akbari H, Macyszyn L, Da X, et al. Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity. Radiology. 2014;273(2):502-10. doi:10.1148/radiol.14132458
22. Lemée JM, Clavreul A, Menei P. Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. Neuro Oncol. Oct 2015;17(10):1322-32. doi:10.1093/neuonc/nov119
23. Chow D, Chang P, Weinberg B, Bota D, Grinband J, Filippi C. Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. AJR American journal of roentgenology. 2018;210(1):30-38. doi:10.2214/ajr.17.18754
24. Lundy P, Domino J, Ryken T, et al. The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update. Journal of neuro-oncology. 2020;150(2):95-120. doi:10.1007/s11060-020-03597-3
25. Jiang T, Nam D, Ram Z, et al. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer letters. 2020;doi:10.1016/j.canlet.2020.10.050
26. Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. Jul 2018;15(7):422-442. doi:10.1038/s41571-018-0003-5
27. Gatson N, Bross S, Odia Y, et al. Early imaging marker of progressing glioblastoma: a window of opportunity. Journal of neuro-oncology. 2020;148(3):629-640. doi:10.1007/s11060-020-03565-x
28. Winterstein M, Münter M, Burkholder I, Essig M, Kauczor H, Weber M. Partially resected gliomas: diagnostic performance of fluid-attenuated inversion recovery MR imaging for detection of progression. Radiology. 2010;254(3):907-16. doi:10.1148/radiol09090893
29. Ito-Yamashita T, Nakasu Y, Mitsuya K, Mizokami Y, Namba H. Detection of tumor progression by signal intensity increase on fluid-attenuated inversion recovery magnetic resonance images in the resection cavity of high-grade gliomas. Neurologia medico-chirurgica. 2013;53(7):496-500. doi:10.2176/nmc.53.496
30. Sarbu N, Oleaga L, Valduvieco I, Pujol T, Berenguer J. Increased signal intensity in FLAIR sequences in the resection cavity can predict progression and progression-free survival in gliomas. Neurocirugia (Asturias, Spain). 2016;27(6):269-276. doi:10.1016/j.neucir.2016.04.002
31. Bette S, Gempt J, Huber T, et al. FLAIR signal increase of the fluid within the resection cavity after glioma surgery: generally valid as early recurrence marker? Journal of neurosurgery. 2017;127(2):417-425. doi:10.3171/2016.8.Jns16752
32. Li Y, Zhang ZX, Huang GH, et al. A systematic review of multifocal and multicentric glioblastoma. J Clin Neurosci. Jan 2021;83:71-76. doi:10.1016/j.jocn.2020.11.025
33. Berzero G, Di Stefano A, Ronchi S, et al. IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro-oncology. 2020;doi:10.1093/neuonc/noaa258
34. Tabor JK, Bonda D, LeMonda BC, D'Amico RS. Neuropsychological outcomes following supratotal resection for high-grade glioma: a review. J Neurooncol. May 2021;152(3):429-437. doi:10.1007/s11060-021-03731-9
35. Moiraghi A, Roux A, Peeters S, et al. Feasibility, Safety and Impact on Overall Survival of Awake Resection for Newly Diagnosed Supratentorial IDH-Wildtype Glioblastomas in Adults. Cancers (Basel). Jun 10 2021;13(12)doi:10.3390/cancers13122911
36. Bettag C, Schregel K, Langer P, et al. Endoscope-assisted fluorescence-guided resection allowing supratotal removal in glioblastoma surgery. Neurosurg Focus. Jan 2021;50(1):E3. doi:10.3171/2020.10.Focus20560
37. Jackson C, Choi J, Khalafallah AM, et al. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neurooncol. Jul 2020;148(3):419-431. doi:10.1007/s11060-020-03556-y
38. Ene CI, Cimino PJ, Fine HA, Holland EC. Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients. Neurosurg Focus. Oct 2020;49(4):E11. doi:10.3171/2020.7.Focus20418
39. Dimou J, Beland B, Kelly J. Supramaximal resection: A systematic review of its safety, efficacy and feasibility in glioblastoma. J Clin Neurosci. Feb 2020;72:328-334. doi:10.1016/j.jocn.2019.12.021
40. Roh TH, Kang SG, Moon JH, et al. Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. J Neurosurg. Mar 1 2019;132(3):895-901. doi:10.3171/2018.12.Jns182558
41. Ahmadipour Y, Kaur M, Pierscianek D, et al. Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma. J Neurol Surg A Cent Eur Neurosurg. Jul 2019;80(4):262-268. doi:10.1055/s-0039-1685170
42. Esquenazi Y, Friedman E, Liu Z, Zhu JJ, Hsu S, Tandon N. The Survival Advantage of "Supratotal" Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. Neurosurgery. Aug 1 2017;81(2):275-288. doi:10.1093/neuros/nyw174
43. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. Oct 10 2013;155(2):462-77. doi:10.1016/j.cell.2013.09.034
44. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. May 18 2010;17(5):510-22. doi:10.1016/j.ccr.2010.03.017
45. Khan MN, Poulin A, Essig M. Fourth Ventricular Lesions in Metastatic Gliomas: A Rare Predilection? Brain Tumor Res Treat. Apr 2017;5(1):24-29. doi:10.14791/btrt.2017.5.1.24